Elsevier Inc.

SHERPA: Unknown

People

  1. Devlin
    Devlin
  2. Giralt
    Giralt
  3. Zhang
    Zhang
  4. Perales
    Perales
  5. Shah
    Shah
  6. Papadopoulos
    Papadopoulos
  7. Ponce
    Ponce
  8. Jakubowski
    Jakubowski
  9. Dahi
    Dahi
  10. Castro-Malaspina
    Castro-Malaspina

Groups

  1. Epidemiology and Biostatistics (481)
  2. Biostatistics Service (402)
  3. Department of Medicine (317)
  4. Survivorship Research (285)
  5. Center for Hematologic Malignancies (178)
  6. Hematologic Malignancies, Division of (177)
  7. Surgery (174)
  8. Radiation Oncology, Department of (163)
  9. Bone Marrow Transplant (147)
  10. GSK Faculty (144)
Search Within
  1. "Meeting abstract"
  2. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (481)
Groups
  1. Epidemiology and Biostatistics (481)
  2. Biostatistics Service (402)
  3. Department of Medicine (317)
  4. Survivorship Research (285)
  5. Center for Hematologic Malignancies (178)
  6. Hematologic Malignancies, Division of (177)

More Groups

People
  1. Sean Devlin (121)
  2. Sergio Giralt (120)
  3. Zhigang Zhang (118)
  4. Miguel-Angel Perales (80)
  5. Gunjan Shah (60)
  6. Juliet Barker (57)

More People

Years
  1. 2024 (12)
  2. 2023 (42)
  3. 2022 (34)
  4. 2021 (17)
  5. 2020 (40)
  6. 2019 (29)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (156)
  2. Biology of Blood and Marrow Transplantation (125)
  3. Journal of Thoracic Oncology (51)
  4. Gynecologic Oncology (45)
  5. Clinical Lymphoma, Myeloma and Leukemia (30)
  6. Journal of Sexual Medicine (24)

More Publications

Results (481)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vaginal/vulvar symptoms with lasofoxifene versus fulvestrant in ESR1-Mutated, Er+/Her2-metastatic breast cancer patients
    Meeting Abstract

    Goldfarb, S. B.; Sammons, S. L.; Meisel, J. L.; Pluard, T. J.; Jenkins, S. N.; Komm, B.; Carroll, D.; Portman, D. J.
    Journal of Sexual Medicine (2023)

    Fulltext@MSK | Save
  • Suggestions for modifications to the female sexual function index to be inclusive of all populations - Cognitive interviews with sexual and gender minority and heterosexual persons
    Meeting Abstract

    Lynch, K.; Austria, M.; Le, T.; Walters, C. B.; Vickers, A.; Long-Roche, K.; Atkinson, T.; Carlsson, S.
    Journal of Sexual Medicine (2023)

    Fulltext@MSK | Save